Open AccessThe legalization of cannabinoid products and standardizing cannabis-drug development in the United States: a brief report
Author(s) -
Jahan P. Marcu
Publication year - 2020
Publication title -
dialogues in clinical neuroscience
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.11
H-Index - 87
eISSN - 1958-5969
pISSN - 1294-8322
DOI - 10.31887/dcns.2020.22.3/jmarcu
Subject(s) - cannabis , legalization , popularity , cannabinoid , business , recreation , population , recreational drug , drug , medicine , environmental health , pharmacology , psychiatry , political science , law , receptor
This brief report covers recent advances in cannabis and cannabinoid regulation and drug approval. The popularity of cannabis and cannabinoid products continues to rise, and these products are available for the majority of the population in the United States to purchase as easily as alcohol. Although many states have approved programs and research licenses, these activities and products all remain federally illegal. The solution may be for the United States to offer multiple pathways for product approval that adapt to the diversity of the products and the needs of the consumer. Multiple pathways for market approval would protect public health, whether the public is using cannabis and cannabinoids as a medicine, a wellness product, or as a recreational substance.
.